MARKET

RUBY

RUBY

Rubius Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8001
+0.0108
+1.37%
Opening 10:48 08/11 EDT
OPEN
0.7900
PREV CLOSE
0.7893
HIGH
0.8200
LOW
0.7810
VOLUME
70.65K
TURNOVER
43.37K
52 WEEK HIGH
24.84
52 WEEK LOW
0.6500
MARKET CAP
72.29M
P/E (TTM)
-0.3591
1D
5D
1M
3M
1Y
5Y
BRIEF-Rubius Therapeutics Posts Q2 Loss Per Share $0.49
BRIEF-Rubius Therapeutics Posts Q2 Loss Per Share $0.49
Reuters · 2d ago
Rubius Therapeutics: Q2 Earnings Insights
  Rubius Therapeutics (NASDAQ:RUBY) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 2d ago
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Rubius Therapeutics press release (<span class="ti...
Seekingalpha · 2d ago
Rubius Therapeutics Q2 EPS $(0.49) Beats $(0.53) Estimate
Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 12.5 percent increase over losses of $(0.56) per share from
Benzinga · 2d ago
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell ...
GlobeNewswire · 07/26 12:00
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell ...
GlobeNewswire · 07/14 12:00
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings Potentially Translatable to Multiple T Cell-Mediated Autoimmune Dis...
GlobeNewswire · 06/22 12:00
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Benzinga · 06/21 08:44
More
No Data
Learn about the latest financial forecast of RUBY. Analyze the recent business situations of Rubius Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
16.67%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RUBY stock price target is 6.80 with a high estimate of 20.00 and a low estimate of 1.000.
High20.00
Average6.80
Low1.000
Current 0.8001
EPS
Actual
Estimate
-0.49-0.37-0.24-0.12
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 152
Institutional Holdings: 92.86M
% Owned: 102.77%
Shares Outstanding: 90.36M
TypeInstitutionsShares
Increased
39
2.49M
New
20
889.48K
Decreased
33
2.68M
Sold Out
11
270.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.47%
Pharmaceuticals & Medical Research
+0.08%
Key Executives
Non-Executive Chairman/Independent Director
Noubar Afeyan
President/Chief Executive Officer/Director
Pablo Cagnoni
Chief Financial Officer
Jose Carmona
Chief Operating Officer
Dannielle Appelhans
Chief Scientific Officer
Laurence Turka
Secretary
Maiken Keson-Brookes
Director
David Epstein
Director
Susanne Schaffert
Independent Director
Francis Cuss
Independent Director
Natalie Holles
Independent Director
Michael Rosenblatt
Independent Director
Catherine Sohn
Independent Director
Jonathan Symonds
No Data
No Data
About RUBY
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Webull offers kinds of Rubius Therapeutics Inc stock information, including NASDAQ:RUBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RUBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RUBY stock methods without spending real money on the virtual paper trading platform.